SCHEMBL12963909

SCHEMBL12963909

CCc1ccnc2[nH]c(C3CC3)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA1 P30542 2/20 0.38
▸ TMIGD3 P0DMS9 1/20 0.38
▸ PBK Q96KB5 7/20 0.36
▸ PDE2A O00408 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ PARP1 P09874 3/20 0.34
▸ BRD4 O60885 1/20 0.34
▸ PARP2 Q9UGN5 1/20 0.34
▸ HTR2A P28223 1/20 0.33
▸ HTR2C P28335 1/20 0.33
▸ HTR2B P41595 1/20 0.33
▸ PDK2 Q15119 1/20 0.33
▸ PDK4 Q16654 1/20 0.33
▸ AURKA O14965 1/20 0.33
▸ MAP4K4 O95819 1/20 0.33
▸ PAK4 O96013 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3957784 0.94 ADORA2B (0.35) ADORA1TMIGD3PBKTSHR
SCHEMBL1917418 0.80 BRD4 (0.44) ADORA1PBKALDH1A1POLBMAPT
SCHEMBL12964001 0.79 PBK (0.43) ADORA1PBKPOLBRET
SCHEMBL1917392 0.76 ADORA3 (0.39) PBKALDH1A1POLBMAPTHPGD
SCHEMBL3148674 0.76 CCR1 (0.39) ADORA1PBKALDH1A1POLBMAPT
SCHEMBL4149204 0.75 KDM5B (0.48) PBKPARP1
SCHEMBL4164391 0.74 PARP1 (0.44) PBKALDH1A1PARP1HTR2CPDK2
SCHEMBL3949386 0.74 BRD4 (0.40) ADORA1BRD4PDK2PDK4GSK3B
SCHEMBL3948904 0.74 PDK2 (0.37) ADORA1PBKALDH1A1POLBMAPT
SCHEMBL3950357 0.73 JAK3 (0.38) ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011002772-A1 IMIDAZOPYRIDINE DERIVATIVES AND PBK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE, INC. (JP) 2011-01-06 — — WO disclosed
Send feedback